XML 61 R50.htm IDEA: XBRL DOCUMENT v3.23.2
Business concentrations - Additional Information (Details)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2023
USD ($)
Jun. 30, 2023
USD ($)
Mayne Pharma [Member]    
Concentration Risk [Line Items]    
Customer license revenue percentage 100.00% 100.00%
Royalty receivable short term portion $ 0.8 $ 0.8
Royalty receivable long term portion $ 19.8 $ 19.8
Theramex [Member]    
Concentration Risk [Line Items]    
Customer license revenue percentage 100.00% 100.00%
Royalty receivable short term portion $ 0.8 $ 0.8